Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system
Introduction: Chimeric Antigen Receptor (CAR) T cells have tremendous potentials for cancer treatment; however, various challenges impede their universal use. These restrictions include the poor function of T cells in tumor microenvironments, the shortage of tumor-specific antigens and, finally, the...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137923001244 |
| _version_ | 1797271332951425024 |
|---|---|
| author | Abbas Hajifathali Maryam Vahdat Lasemi Maryam Mehravar Mohammad Reza Moshari Afshin Mohammad Alizadeh Elham Roshandel |
| author_facet | Abbas Hajifathali Maryam Vahdat Lasemi Maryam Mehravar Mohammad Reza Moshari Afshin Mohammad Alizadeh Elham Roshandel |
| author_sort | Abbas Hajifathali |
| collection | DOAJ |
| description | Introduction: Chimeric Antigen Receptor (CAR) T cells have tremendous potentials for cancer treatment; however, various challenges impede their universal use. These restrictions include the poor function of T cells in tumor microenvironments, the shortage of tumor-specific antigens and, finally, the high cost and time-consuming process, as well as the poor scalability of the method. Creative gene-editing tools have addressed each of these limitations and introduced next generation products for cell therapy. The clustered regularly interspaced short palindromic repeats-associated endonuclease 9 (CRISPR/Cas9) system has triggered a revolution in biology fields, as it has a great capacity for genetic manipulation. Method: In this review, we considered the latest development of CRISPR/Cas9 methods for the chimeric antigen receptor T cell (CAR T)-based immunotherapy. Results: The ability of the CRISPR/Cas9 system to generate the universal CAR T cells and also potent T cells that are persistent against exhaustion and inhibition was explored. Conclusion: We explained CRISPR delivery methods, as well as addressing safety concerns related to the use of the CRISPR/Cas9 system and their potential solutions. |
| first_indexed | 2024-03-07T14:00:11Z |
| format | Article |
| id | doaj.art-821d6dd967814410ad748efafdb11bfe |
| institution | Directory Open Access Journal |
| issn | 2531-1379 |
| language | English |
| last_indexed | 2024-03-07T14:00:11Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hematology, Transfusion and Cell Therapy |
| spelling | doaj.art-821d6dd967814410ad748efafdb11bfe2024-03-07T05:28:58ZengElsevierHematology, Transfusion and Cell Therapy2531-13792024-01-014615866Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR systemAbbas Hajifathali0Maryam Vahdat Lasemi1Maryam Mehravar2Mohammad Reza Moshari3Afshin Mohammad Alizadeh4Elham Roshandel5Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IranHematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IranHematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IranSchool of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranHematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Ayatollah Taleghani Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranHematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Corresponding author at: Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.Introduction: Chimeric Antigen Receptor (CAR) T cells have tremendous potentials for cancer treatment; however, various challenges impede their universal use. These restrictions include the poor function of T cells in tumor microenvironments, the shortage of tumor-specific antigens and, finally, the high cost and time-consuming process, as well as the poor scalability of the method. Creative gene-editing tools have addressed each of these limitations and introduced next generation products for cell therapy. The clustered regularly interspaced short palindromic repeats-associated endonuclease 9 (CRISPR/Cas9) system has triggered a revolution in biology fields, as it has a great capacity for genetic manipulation. Method: In this review, we considered the latest development of CRISPR/Cas9 methods for the chimeric antigen receptor T cell (CAR T)-based immunotherapy. Results: The ability of the CRISPR/Cas9 system to generate the universal CAR T cells and also potent T cells that are persistent against exhaustion and inhibition was explored. Conclusion: We explained CRISPR delivery methods, as well as addressing safety concerns related to the use of the CRISPR/Cas9 system and their potential solutions.http://www.sciencedirect.com/science/article/pii/S2531137923001244Cancer treatmentAdoptive immunotherapyChimeric antigen receptorGene therapyCRISPR/Cas9 |
| spellingShingle | Abbas Hajifathali Maryam Vahdat Lasemi Maryam Mehravar Mohammad Reza Moshari Afshin Mohammad Alizadeh Elham Roshandel Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system Hematology, Transfusion and Cell Therapy Cancer treatment Adoptive immunotherapy Chimeric antigen receptor Gene therapy CRISPR/Cas9 |
| title | Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system |
| title_full | Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system |
| title_fullStr | Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system |
| title_full_unstemmed | Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system |
| title_short | Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system |
| title_sort | novelty in improvement of car t cell based immunotherapy with the aid of crispr system |
| topic | Cancer treatment Adoptive immunotherapy Chimeric antigen receptor Gene therapy CRISPR/Cas9 |
| url | http://www.sciencedirect.com/science/article/pii/S2531137923001244 |
| work_keys_str_mv | AT abbashajifathali noveltyinimprovementofcartcellbasedimmunotherapywiththeaidofcrisprsystem AT maryamvahdatlasemi noveltyinimprovementofcartcellbasedimmunotherapywiththeaidofcrisprsystem AT maryammehravar noveltyinimprovementofcartcellbasedimmunotherapywiththeaidofcrisprsystem AT mohammadrezamoshari noveltyinimprovementofcartcellbasedimmunotherapywiththeaidofcrisprsystem AT afshinmohammadalizadeh noveltyinimprovementofcartcellbasedimmunotherapywiththeaidofcrisprsystem AT elhamroshandel noveltyinimprovementofcartcellbasedimmunotherapywiththeaidofcrisprsystem |